EGFR and non-small cell lung carcinoma: The presence of oncogenic drivers, such as EML4-ALK rearrangement or EGFR activating mutations, in NSCLC patients can also cause an increase in PD-L1 level [11,12] and treatment with specific ALK or EGFR inhibitors has been shown to reduce this expression [11].